key: cord-0857525-nixfkclx authors: Chakraborty, Chiranjib; Bhattacharya, Manojit; Sharma, Ashish Ranjan title: Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity date: 2021-06-27 journal: Rev Med Virol DOI: 10.1002/rmv.2270 sha: 740708b3114d052fafeec85765938f740d2337db doc_id: 857525 cord_uid: nixfkclx Newly arising variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are now a threat to global public health and are creating COVID‐19 surges in different countries. At the same time, there is limited knowledge about these emerging variants. Even if research data are available, it is varyingly scattered. In this review, we have discussed the appearance of significant alarming SARS‐CoV‐2 variants in the entire world. The study also discusses the properties of the substantial variant of concern (VOC) variants such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon) and B.1.429 (Epsilon). At the same time, the characteristic properties of some significant variant of interest (VOI) variants like B.1.525 (Eta), B.1.526 (Iota) (sublineage B.1.526.1), B.1.617 (sublineages B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3), P.2 (Zeta), P.3 (Theta), B.1.616 and B.1.427 have also been discussed. Here, we have explained some essential mutations for the VOC and VOI variants such as K417T/N, L452R, E484K, N501Y, D614G and P681R. Consecutively, we also highlighted the crucial clinical characteristics of the variants, such as transmissibility, infectivity, re‐infectivity, immune escape, vaccine activity and vaccine escape. Our comprehensive review will provide updated information on the newly appearing variants of SARS‐CoV‐2 and help the researchers to formulate strategies to curtail the COVID‐19 pandemic. The devastating effects of the COVID-19 pandemic have brought noteworthy health crises throughout the globe. The pandemic has generated significant social problems and even has shut down communities in different countries throughout the world. [1] [2] [3] [4] In addition, the world is facing an economic crisis, creating a vulnerable condition in developing world countries. As of 11 June 2021, COVID-19 has infected 174,502,686 peoples as per World Health Organization (WHO) data. Meanwhile, 3,770,361 peoples have died from this disease so far. The scientists are putting their best efforts into searching the different therapeutic and development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [5] [6] [7] [8] The rise of infections and death cases has been observed in several world regions after the spread of novel SARS-CoV-2 variants. Due to a new variant, COVID-19 cases gradually increased in the UK in November 2020. The country has to go through a lockdown to contain the spread of variants. 9 Similarly, due to the spread of a novel SARS-CoV-2 variant, a steady rise of COVID-19 cases was noted in India. The spread of the variant has created a second wave of infection of COVID-19 cases in the country. The country has currently imposed lockdown partially in several regions of the country. 10 Newly emerging variants are now a threat to global public health gain. The genome sequence data of SARS-CoV-2 were first provided by the Chinese researcher, Professor Zhang, and his colleagues at Fudan University in the first week of January 2020. The team deposited the sequence into the GenBank for the use of further studies. 11, 12 After the SARS-CoV-2 detection in China, it was observed that several SARS-CoV-2 new variants came into existence with time and different geographic locations as a consequence of genetic evolution (Figure 1 ). SARS-CoV-2 new variants genome sequences are submitted quickly to the global initiative on sharing all influenza data (GISAID) and GenBank databases. Around the world, most scientists are submitting their genome sequences of the variants into the GISAID database, and it is a well-known database for the genome sequences for this virus. As of 12 June 2021, 1,938,109 sequences have been submitted to the GISAID database. Utilising this database, scientists are trying to delineate several vital factors of the new variants, such as mutations, pathogenicity, virulence, transmissibility and antigenicity. It has been observed that mutations in the genome sequence have generated a definite change, giving rise to the new variants of the SARS-CoV-2. 13, 14 Mutations are prevalent in the viral genomes. Mutations occur due to the consequences of viral replication. 15 In general, higher mutation rates are recorded in RNA viruses compared to DNA viruses. 16 However, fewer mutations are noted in the coronaviruses than in RNA viruses because the virus can produce an enzyme with proof correction machinery. This enzyme corrects several errors that occur during replication. 16 Nevertheless, it has been observed that this virus has made several single mutations throughout the genome compared to the wild type (genome F I G U R E 1 A timeline depicting the origin time of some significant variants of SARS-CoV-2. The variants of concern are marked into the red box and variants of interest marked into the violet box. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 from the Wuhan strain in China, which was sequenced in the first week of January 2020). 17, 18 Several factors are associated with the generation of viral mutations. One of the significant causes is the intervention of the human immune system. The machinery involved in the immune system can cause interference in the genome to introduce viral mutations. Another important cause of mutation in the genome of this virus is the rapid transmission and quick spread rate. Moreover, RNA viruses are prone to rapid mutations as compared to DNA viruses. These factors provide considerable opportunities for SARS-CoV-2 with natural selection, which generates favourable and rare-acted mutations ( Figure 2 ). 19 24, 25 Similarly, VOI appeared due to amino acid alterations associated with increased community transmission, and these variants have been detected in various countries. 24, 25 In this manuscript, we have discussed the alarming appearance of these variants throughout the world. The article also discusses the properties of the significant VOCs and VOIs, important mutations for the VOCs, and VOIs such as K417T/N, L452R, E484K, N501Y, D614G and P681R. Consecutively, we have illustrated the transmissibility, infectivity, re-infectivity immune escape, vaccine activity and vaccine escape of new variants. Several SARS-CoV-2 variants have appeared as a global threat throughout the world (Figure 3 ). It has raised various major questions among scientists about the nature of the variants and their consequences. One of the significant variants is the B.1.1.7, which originated in the UK. 26 Frampton et al. found that the disease was augmented due to the transmissibility of the variant. Using a cohort study in the UK hospital, the researchers concluded that the variant was not associated with the severity of the disease in the hospitalised cohort. 27 Another lineage that was found spreading throughout South Africa was B.1.351 variant. 28 were detected from Colorado, USA. Both of these variants spread throughout the USA and are now a public health concern in USA. 32 Jacobson et al. found these two variants re-infected the healthcare Acquisitions of several mutations give rise to several significant variants, and natural selection determines the fate of a newly generated mutation. Therefore, natural selection is the determinantal factor about the existence and the consequence of the variants. The B.1.351 variant is also defined as 20H/501Y.V2, as described by the Nextstrain database, and GH/501Y.V2, as described by the GISAID database. Therefore, 20H/501Y.V2 and GH/501Y.V2 are known as Nextstrain clade and GISAID clade, respectively. The variant was detected from South Africa in December 2020 and was traced in the Eastern Cape region. After that, it was detected from the KwaZulu and Western Cape regions. 38 The variant was even detected from Zambia, located in the southern part of Africa, 39 indicating circulation of this variant throughout the country. Simultaneously, the variant also got transferred to various countries. Yadav et al. reported that the variant was detected in India, imported through a traveller. 40 In March 2021, the variant was identified in Germany through a rapid antigen test. 41 During January-February 2021, the clinical laboratory identified the variant from Maryland, USA. 42 It was observed that this variant has more hACE2 binding affinity. The researchers showed that the variant has 4.62 times more RBD-hACE2 binding affinity than the RBD of SARS-CoV-2. 43 The variant is also associated with public health hazards such as re-infections. Staub T A B L E 1 SARS-CoV-2 variant of concern and their mutations in RBD and S-protein (other than RBD region) Sl no. Country of origin (Figure 4a ). S-glycoprotein mutations, other than the RBD, are S13I, W152C and D614G. After continuous surveillance during January-March 2021, these two variants were identified from Colorado, USA, and were found highly contagious. These variants are accountable for more severe illness. 32 Another study found post-vaccination infections among healthcare workers by these variants in the northern part of California. 53 Some significant mutations are found in the S-glycoprotein of this strain. The one considerable mutation is located in the RBD (L452R). However, mutation (E484K) was observed in the RBD of some samples, while it was found absent in others. 53 The P.2 variant is also known as 20B/S.484K, as defined by the Nextstrain database. Therefore, 20B/S.484K is also known as Nextstrain clade. Significant mutations are found in the S-glycoprotein of this strain (F565L, D614G and V1176F). Other than S-glycoprotein, one considerable mutation has been observed in the RBD (E484K) (Figure 4b ). Several significant mutations are observed in the VOCs and VOIs (Figure 5a and 5b) . We also noted the country-wise significant mutations for the VOCs and VOIs in Table 3 . Some important mutations are described below. 68 The mutation is also associated with the re-infection, as noted in the SARS-CoV-2 re-infected patients in Brazil. 69 This significant mutation is also found in the S-glycoprotein protein outside the RBD region. It is located in the VOI B. 88 We also recorded the vaccine escape mutations of the new variants in Table 4 . However, the development of a next-generation vaccine for COVID-19 may be one solution for vaccine escape. This nextgeneration vaccine should posse alternative epitopes from the different emerging variants. Bhattacharya et al. developed a vaccine using alternative epitopes from the significant variants of SARS CoV-2 and Wuhan strain through immunoinformatics approach. 95 However, more research data are needed in this direction. Abbreviations: RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. 12 of 14 -CHAKRABORTY ET AL. SARS-CoV-2 variants and ending the COVID-19 pandemic Coronavirus disease 2019 (COVID-19): a literature review SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis A SARS-CoV-2 vaccine candidate: in-silico cloning and validation Immunotherapies and immunomodulatory approaches in clinical trials-a mini review Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach New variant of SARS-CoV-2 in UK causes surge of COVID-19 The current second wave and COVID-19 vaccination status in India A new coronavirus associated with human respiratory disease in China COVID-19: learning from lessons to guide treatment and prevention interventions On the origin and continuing evolution of SARS-CoV-2 SARS-CoV-2 genomics: an Indian perspective on sequencing viral variants We shouldn't worry when a virus mutates during disease outbreaks A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping Mutations strengthened SARS-CoV-2 infectivity Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines Mechanisms of viral mutation SARS-CoV-2 Brazil variants in Latin America: more serious research urgently needed on public health and vaccine protection Structural analysis of the novel variants of SARS-CoV-2 and forecasting in North America Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants Weekly epidemiological update. Special edition: Proposed Working Definitions of SARS-CoV-2 Variants of Interest and Variants of Concern Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19 Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01 Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Identification of and surveillance for the SARS-CoV-2 variants B.1.427 and B.1.429-Colorado Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center Emergence of SARS-CoV-2 b.1.1.7 lineage-United States Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England Implications of the novel mutations in the SARS-CoV-2 genome for transmission, disease severity, and the vaccine development Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 spike is impacted by the B.1.1.7 variant. Immunity Detection of a SARS-CoV-2 variant of concern in South Africa Detection of B.1.351 SARS-CoV-2 variant strain-Zambia Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs) Linked clusters of SARS-CoV-2 variant B.1.351-Maryland SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity Case series of four reinfections with a SARS-CoV-2 B.1.351 variant Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus Covid-19: researchers find higher than expected reinfections with P.1 variant among the Brazilian Amazon SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State Emergence and spread of SARS-CoV-2 lineages B.1.1. 7 and P.1 in Italy Genome sequences of SARS-CoV-2 P.1 (variant of concern) and P.2 (variant of interest) identified in Uruguay Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization COVID-19 weekly epidemiological update SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. BioRxiv. 2021:437925 Genomic surveillance activities unveil the introduction of the SARS-CoV-2 B.1.525 variant of interest in Brazil: case report High prevalence of SARS-CoV-2 B.1.1.7 (UK variant) and the novel B.1.525 lineage in Oyo State Coronavirus variants are spreading in India-what scientists know so far Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccines Neutralization potential of covishield vaccinated individuals sera against B.1.617.1. Clin Infect Dis Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies Novel SARS-CoV-2 variant derived from clade 19B, France. Emerg Infect Dis Novel SARS-CoV-2 variants: the pandemics within the pandemic Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe Genomic evidence of a SARS-cov-2 reinfection case with E484K spike mutation in Brazil Inferring the association between the risk of COVID-19 case fatality and N501Y substitution in SARS-CoV-2 The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant The SARS-CoV-2 spike variant D614G favors an open conformational state Spike mutation D614G alters SARS-CoV-2 fitness The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization Extensive genetic diversity with novel mutations in spike glycoprotein of SARS-CoV-2, Bangladesh in late 2020 Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study Emergence of a novel SARS-CoV-2 variant in Southern California Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo Structure-function analyses of new SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.28.1: clinical, diagnostic, therapeutic and public health implications Analysis of the potential impact of genomic variants in global SARS-CoV-2 genomes on molecular diagnostic assays Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant Will SARS-CoV-2 variants of concern affect the promise of vaccines? Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals Vaccine-escape and fast-growing mutations in the United Kingdom, the United States Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/ 01 (B.1.1.7): an exploratory analysis of a randomised controlled trial BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant Emergency use authorization (EUA) for an unapproved product review memorandum identifying information Novel SARS-CoV-2 variants: the pandemics within the pandemic New SARS-CoV-2 variants-clinical, public health, and vaccine implications A next-generation vaccine candidate using alternative epitopes to protect against Wuhan and all significant mutant variants of SARS-CoV-2: an immunoinformatics approach. Aging and disease Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, reinfectivity, immune escape and vaccines activity The authors are grateful to the authorities of Adamas University, India, Fakir Mohan University, India and Hallym University, Republic of Korea. The authors declare no conflict of interest. Conceptualization, methodology, data curation, writing, supervision: Chiranjib Chakraborty. Validation, formal analysis: Manojit Bhattacharya. Formal analysis, review and editing: Ashish Ranjan Sharma.All authors reviewed and approved the final version of the manuscript. The authors confirm that the data supporting the findings of this study are available within the article. https://orcid.org/0000-0002-3958-239X